Breast Cancer Cells Have To Learn To Walk Before They Can Run

Main Category: Breast Cancer
Also Included In: Cancer / Oncology
Article Date: 01 Jan 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Early-stage breast cancer that has not yet invaded the surrounding tissues may already contain highly motile cells, bringing the tumor one step closer to metastasis, report researchers at the Salk Institute for Biological Studies.

Their study, published in the Dec. 30 issue of the Journal of Cell Biology, suggests that these cells, although not yet invasive, could wander off along milk ducts and seed new tumors within the same breast. "A lack of invasion suggested a lack of motility," says lead author Gray Pearson, Ph.D, a postdoctoral researcher in the Molecular and Cell Biology Laboratory at the Salk, "but that's not so."

"This is an exciting finding because it suggests that cells might acquire migratory properties much earlier than expected," says senior author Tony Hunter, Ph.D., a professor in the Molecular and Cell Biology Laboratory.

Due to improved screening programs, most breast tumors are discovered at an early stage when they are still small and confined. In such cases, cancer cells have not grown into the surrounding tissues and remain within the borders of a duct, the most common site where invasive breast cancer arises. These tumors are known as DCIS (ductal carcinoma in situ).

The standard treatment for DCIS is lumpectomy, the surgical removal of the tumor and surrounding tissue. Approximately 16% of DCIS patients treated with lumpectomy alone develop recurrent breast cancer growth within 5 years of treatment. One of the questions faced by oncologists and patients is whether they should add gamma radiation after undergoing surgery to catch straying tumor cells and reduce the risk of recurrent breast cancer. Currently, the decision is based solely on the size of the tumor.

"Our findings suggest that, if a DCIS contains these highly motile cells, the patient may have an increased risk for recurrent growth," says Pearson. "Under these circumstances you would consider adding radiation treatment regardless of tumor size."

While the presence of highly motile cells may guide treatment decisions in the future, the researchers have yet to show that wandering cells do indeed influence a patient's outcome, cautions Pearson.

In their study, the Salk researchers used a tissue culture model that recreates the duct of the mammary gland. They embedded human cells, isolated from breast tissue, in a three-dimensional matrix that mimics their natural surroundings. These cells spontaneously develop into so called acini, hollow structures resembling tiny milk ducts.

Then they turned on the ERK1/2 MAP kinase pathway, a signaling cascade frequently activated during the development of tumors, and watched in real time as breast cancer cells learned how to walk. "We quickly realized that there was a significant cell movement, which was quite surprising," recounts Pearson. "Within 24 hours, a large number of these spheres had lost their organization, and the cells started to dance around."

While dangerously invasive cells can squeeze through the basement membrane and make a run for the surrounding tissue, motile cells still could not escape the confines of the ERK-activated acini. "But the acquisition of motility prior to invasion presumably lowers the barrier for future invasive growth," explains Pearson.

"The advent of live-cell imaging allows us to watch labeled cells move around in tissues and learn a lot about their behavior, which wouldn't be revealed in cultured cells," says Hunter.

With the next step, Pearson hopes to identify molecular markers for breast cancer cell motility that will help oncologists to diagnose patients who are at higher risk of metastasis.

The Salk Institute for Biological Studies in La Jolla, California, is an independent nonprofit organization dedicated to fundamental discoveries in the life sciences, the improvement of human health and the training of future generations of researchers. Jonas Salk, M.D., whose polio vaccine all but eradicated the crippling disease poliomyelitis in 1955, opened the Institute in 1965 with a gift of land from the City of San Diego and the financial support of the March of Dimes.

Salk Institute